skip to content

Who Uses CDD?

Organizations that benefit from CDD


  • ASINEX
  • Broad Institute
  • Cedars-Sinai Medical Center
  • Columbia University
  • Cornell University
  • Drugs for Neglected Diseases initiative
  • Fred Hutchinson Cancer Research Center
  • Harvard University
  • Indiana University
  • Indiana University-Purdue University Indianapolis
  • Johns Hopkins University
  • Louisiana State University
  • Marine Biological Laboratory
  • Massachusetts Institute of Technology
  • Myelin Repair Foundation
  • Ohio State University
  • Public Library of Science
  • San Francisco VA Medical Center
  • Scripps Research Institute
  • Seattle Biomedical Research Institute
  • Semafore Pharmaceuticals, Inc.
  • Stanford University
  • St. Jude Children's Research Hospital
  • Torrey Pines Institute for Molecular Studies
  • UCSF General Hospital
  • University of California, Berkeley
  • University of California, Los Angeles
  • University of California, San Francisco
  • University of California, Santa Cruz
  • University of Cape Town
  • University of Mississippi
  • University of North Carolina
  • University of Pennsylvania
  • University of Sydney
  • University of Texas
  • University of Washington

Testimonials

"Five years ago our lab tested 20 compounds a year with no way to handle 200. Today, with CDD’s software, we can fully process 3,000 new compounds per year and advance the best compounds to late-stage development."

— Dr. James McKerrow, UCSF

"It’s a great tool for mining and sharing data with collaborators. I’ve used a couple of other programs, but they don’t put everything together so intuitively."

— Mary Lynn Baniecki, PhD, Clardy Laboratory, Harvard Medical School

"One of the biggest barriers for academic drug discovery is the poor access to chemical data represented in an intelligent format. CDD presents data and associated tools that capture the relationship between chemical structure and biological activity. Structure-Activity Relationship (SAR) data substantially improve the distributed drug discovery process."

— Christopher Lipinski, PhD, Pfizer, Retired

"Your networks, data sets and models more optimally utilize finite translational R&D resources… this is exactly what is needed today to more rapidly develop new treatments for neglected diseases."

— Gary K. Schoolnik, MD, Stanford University, School of Medicine

"Thanks for your help and to the engineers for the updates – the EC50 calculations are going to save me hours."

— Joe Planer, PhD, University of Washington, School of Medicine

"I was very impressed by the system's simplicity, responsiveness and functionality. It certainly looks better than anything I've seen so far."

— Wayne Best, PhD

"The CDD Database is an extremely elegant platform. I highly recommend it for anyone generating drug discovery data."

— Bryan Roth, M.D., Ph.D., University of North Carolina